Xu Zhenzhen, Liu Lipeng, Cui Zhe, Bi Kewei, Zhang Nan, Zhang Yanfen, Liu Zhongcheng
College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Baoding 071002, China.
Protein Pept Lett. 2018;25(11):966-972. doi: 10.2174/0929866525666181026162216.
FcγRIIb is the only inhibitory IgG receptor, which is divided into three subtypes of FcγRIIb1, FcγRIIb2 and FcγRIIb3. It is mainly responsible for the immune balance in vivo by cross-linking with the activated receptor to intracellular transduction inhibitory signals, and it plays an important biological role in the negative regulation of innate immunity and adaptive immunity. An abnormal expression of FcγRIIb on cells would result in autoimmune diseases, infectious diseases, and so forth.
FcγRIIb modulates immune responses and further treats related diseases by inhibiting the activation of B lymphocytes, monocytes, mast cells, and basophils induced by activating receptors. It can be used in biotherapeutic methods such as monoclonal antibodies, chimeric recombinant proteins, bispecific antibodies, etc. Our increased understanding of FcγRIIb function also has a foundation for further research and development of FcγRIIb, which also provides potentially farreaching therapeutic implications.
FcγRIIb是唯一的抑制性IgG受体,分为FcγRIIb1、FcγRIIb2和FcγRIIb3三种亚型。它主要通过与活化受体交联向细胞内转导抑制性信号来负责体内的免疫平衡,在天然免疫和适应性免疫的负调控中发挥重要生物学作用。细胞上FcγRIIb表达异常会导致自身免疫性疾病、感染性疾病等。
FcγRIIb通过抑制活化受体诱导的B淋巴细胞、单核细胞、肥大细胞和嗜碱性粒细胞的活化来调节免疫反应并进一步治疗相关疾病。它可用于单克隆抗体、嵌合重组蛋白、双特异性抗体等生物治疗方法。我们对FcγRIIb功能的深入了解也为FcγRIIb的进一步研发奠定了基础,这也具有潜在的深远治疗意义。